Literature DB >> 22202064

Curcumin: the multi-targeted therapy for cancer regression.

Dewan Md Sakib Hossain1, Sankar Bhattacharyya, Tanya Das, Gaurisankar Sa.   

Abstract

Tumors are multifaceted; in fact, numerous things happen in synchrony to enable tumor promotion and progression. Any type of cancer is associated with the modification of 300-500 normal genes and characterized by the deregulation of cell signaling pathways at multiple steps leading to cancer phenotype. Thus a proper management of tumorigenesis requires the development of multi-targeted therapies. Several adverse effects associated with present day cancer therapies and the thirsts for multi-targeted safe anticancer drug instigate the use of natural polyphenol, curcumin. It appears to involve a blend of anti-carcinogenic, pro-apoptotic, anti-angiogenic, anti-metastatic, immunomodulatory and antioxidant activities. Also the molecular mechanisms implicated for the pleotropic activities of curcumin are diverse and seem to involve a combination of cell signaling pathways at multiple levels of tumorigenesis. Being a potent scavenger of reactive oxygen species, curcumin also ameliorates systemic toxicity in tumor-bearer. Taken together, by placing particular emphasis on molecular basis of tumor promotion and progression this review summarizes the anti-cancer properties of curcumin that may be exploited for successful clinical cancer prevention.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22202064     DOI: 10.2741/272

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN: 1945-0516


  19 in total

1.  C1206, a novel curcumin derivative, potently inhibits Hsp90 and human chronic myeloid leukemia cells in vitro.

Authors:  Ying-Juan Fan; Yi-Xiang Zhou; Lian-Ru Zhang; Qiao-Fa Lin; Ping-Zhang Gao; Fang Cai; Li-Ping Zhu; Bi Liu; Jian-Hua Xu
Journal:  Acta Pharmacol Sin       Date:  2017-12-07       Impact factor: 6.150

2.  Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects.

Authors:  Ming-Rong Cheng; Qing Li; Tao Wan; Bing He; Jiang Han; Hou-Xiang Chen; Feng-Xiao Yang; Wei Wang; Hong-Zhi Xu; Tao Ye; Bing-Bing Zha
Journal:  World J Gastroenterol       Date:  2012-11-14       Impact factor: 5.742

3.  MEK inhibition prevents tumour-shed transforming growth factor-β-induced T-regulatory cell augmentation in tumour milieu.

Authors:  Dewan M S Hossain; Abir K Panda; Sreeparna Chakrabarty; Pushpak Bhattacharjee; Kirti Kajal; Suchismita Mohanty; Irene Sarkar; Diptendra K Sarkar; Santosh K Kar; Gaurisankar Sa
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

Review 4.  Recent Advances in Anticancer Activity of Novel Plant Extracts and Compounds from Curcuma longa in Hepatocellular Carcinoma.

Authors:  Nighat Gull; Fareeha Arshad; Gowhar A Naikoo; Israr Ul Hassan; Mona Zamani Pedram; Arif Ahmad; Alaa A A Aljabali; Vijay Mishra; Saurabh Satija; Nitin Charbe; Poonam Negi; Rohit Goyal; Ángel Serrano-Aroca; Mazhar S Al Zoubi; Mohamed El-Tanani; Murtaza M Tambuwala
Journal:  J Gastrointest Cancer       Date:  2022-03-14

Review 5.  Curcumin and tumor immune-editing: resurrecting the immune system.

Authors:  Sayantan Bose; Abir Kumar Panda; Shravanti Mukherjee; Gaurisankar Sa
Journal:  Cell Div       Date:  2015-10-12       Impact factor: 5.130

Review 6.  Toll-like receptor-4 modulation for cancer immunotherapy.

Authors:  Shanjana Awasthi
Journal:  Front Immunol       Date:  2014-07-25       Impact factor: 7.561

7.  Curcumin and emodin down-regulate TGF-β signaling pathway in human cervical cancer cells.

Authors:  Pooja Chandrakant Thacker; Devarajan Karunagaran
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

8.  Computer-aided discovery of biological activity spectra for anti-aging and anti-cancer olive oil oleuropeins.

Authors:  Bruna Corominas-Faja; Elvira Santangelo; Elisabet Cuyàs; Vicente Micol; Jorge Joven; Xavier Ariza; Antonio Segura-Carretero; Jordi García; Javier A Menendez
Journal:  Aging (Albany NY)       Date:  2014-09       Impact factor: 5.682

9.  Curcumin Veto the Effects of Osteopontin (OPN) Specific Inhibitor on Leukemic Stem Cell Colony Forming Potential via Promotion of OPN Overexpression.

Authors:  Saeed Mohammadi; Seyed H Ghaffari; Mojgan Shaiegan; Mahin Nikogoftar Zarif; Mohsen Nikbakht; Kamran Alimoghaddam; Ardeshir Ghavamzadeh
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2016-07-01

10.  Emerging glycolysis targeting and drug discovery from chinese medicine in cancer therapy.

Authors:  Zhiyu Wang; Neng Wang; Jianping Chen; Jiangang Shen
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-12       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.